TITLE

Alternative technologies in cervical cancer screening: a randomised evaluation trial

AUTHOR(S)
Anttila, Ahti; Hakama, Matti; Kotaniemi-Talonen, Laura; Nieminen, Pekka
PUB. DATE
January 2006
SOURCE
BMC Public Health;2006, Vol. 6, p252
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Background: Cervical cancer screening programmes have markedly reduced the incidence and mortality rates of the disease. A substantial amount of deaths from the disease could be prevented further by organised screening programmes or improving currently running programmes. Methods/Design: We present here a randomised evaluation trial design integrated to the Finnish cervical cancer screening programme, in order to evaluate renewal of the programme using emerging technological alternatives. The main aim of the evaluation is to assess screening effectiveness, using subsequent cancers as the outcome and screen-detected pre-cancers as surrogates. For the time being, approximately 863,000 women have been allocated to automation-assisted cytology, human papillomavirus (HPV) DNA testing, or to conventional cytology within the organised screening programme. Follow-up results on subsequent cervical cancers will become available during 2007-2015. Discussion: Large-scale randomised trials are useful to clarify effectiveness and cost- effectiveness issues of the most important technological alternatives in the screening programmes for cervical cancer.
ACCESSION #
29362392

 

Related Articles

  • Human papillomavirus infection: an Anonymous Prevalence Study in South Wales, UK. Hibbitts, S.; Rieck, G. C.; Hart, K.; Powell, N. G.; Beukenholdt, R.; Dallimore, N.; McRea, J.; Hauke, A.; Tristram, A.; Fiander, A. N. // British Journal of Cancer;7/17/2006, Vol. 95 Issue 2, p226 

    The objective of this study was to describe human papillomavirus (HPV) prevalence in South Wales in relation to age, cytology and social deprivation. This was an unlinked, prospective, anonymous, population-based study. DNA was purified from 1911 liquid-based cytology samples (mean age 37.7...

  • EVALUATION OF 16,18,45 HPV DNA PROBE -- COMPARISON WITH CERVICAL CYTOLOGY AND FOLLOW-UP. Vrdoljak-Mozetič, Danijela; Kaliterna, Vanja; Štemberger-Papić, Snježana; Verša-Ostojić, Damjana; Rešetar, Renato; Krašević, Maja; Brnčić-Fischer, Alemka; Haller, Herman // Central European Journal of Public Health;2008 Supplement, Vol. 16, pS45 

    Objective: Comparison of 16, 18, 45 HPV DNA probe results with cervical cytology findings and evaluation according to followup cytology or/and histology findings. Materials and Methods: 16,18,45 HPV DNA probe was done as an additional test using the Hybrid capture 2 test kit (Digene, USA) in...

  • The Role of HPV Testing in the Screening and Diagnosis of Cervical Cancer. Khan, Ashfaq M.; Singer, Albert // Asia Pacific Journal of Oncology & Hematology;2009, Vol. 1 Issue 1, p1 

    The article focuses on the role of human papilloma virus (HPV) testing in the screening and diagnosis of cervical cancer. The article notes that the combination of HPV DNA testing and cytology improves the sensitivity of screening for cervical intraepithelial neoplasia (CIN). The article...

  • Human Papillomavirus Testing for Cervical Cancer Screening: Results From a 6-Year Prospective Study in Rural China. Ju-Fang Shi; Belinson, Jerome L.; Fang-Hui Zhao; Pretorius, Robert G.; Jing Li; Jun-Fei Ma; Feng Chen; Wang Xiang; Qin-Jing Pan; Xun Zhang; Wen-Hua Zhang; You-Lin Qiao; Smith, Jennifer S. // American Journal of Epidemiology;Sep2009, Vol. 170 Issue 6, p708 

    Long-term follow-up evaluations of cervical screening approaches are limited in low-resource areas. This prospective study assessed the risk of future cervical intraepithelial neoplasia grade 2 or worse (CIN2+) associated with baseline human papillomavirus (HPV) and cytologic status. In rural...

  • HPV presence precedes abnormal cytology in women developing cervical cancer and signals false negative smears. Zielinski, G D; Snijders, P J F; Rozendaal, L; Voorhorst, F J; Linden, H C van der; Runsink, A P; Schipper, F A de; Meijer, C J L M // British Journal of Cancer;8/1/2001, Vol. 85 Issue 3, p398 

    In a retrospective case-control study, we investigated high-risk HPV DNA presence by general primer GP5+/6+ PCR in the last normal cervical smear in the patient archives (i.e. baseline smear) of 57 women who later developed cervical cancer. Also, normal cervical smears of 114 age-matched control...

  • Performance of cytology and human papillomavirus testing in relation to the menstrual cycle. Sherman, M. E.; Carreon, J. D.; Schiffman, M. // British Journal of Cancer;6/5/2006, Vol. 94 Issue 11, p1690 

    Cervical smears prepared around the time of menses have been linked to unsatisfactory specimens and false negative results; however, it is unclear whether liquid-based cytology is similarly affected and data relating date of last menstrual period (LMP) to human papillomavirus (HPV) DNA testing...

  • ALTERNATIVE SCREENING METHODS WITHIN THE ORGANISED SCREENING PROGRAMME FOR CERVICAL CANCER IN FINLAND. Anttila, Ahti // Central European Journal of Public Health;2008 Supplement, Vol. 16, pS25 

    In Finland the organised screening programme to prevent cervical cancer has been in action since early 1960s. The programme has effectively reduced cervical cancer burden in our country. There are needs still to evaluate potential uses of novel technological alternatives within the programme. A...

  • TREATMENT OF PREINVASIVE CERVICAL LESIONS: IS THERE ANY VALUE IN TESTING FOR HPV DNA POST-TREATMENT? Tan, Jeffrey // Infectious Diseases in Obstetrics & Gynecology;2006, Vol. 2006, p5 

    Treating preinvasive cervical lesions A 2001 Cochrane report suggests there is no overwhelmingly superior surgical technique for eradicating CIN [23]. Regardless of treatment approach, the risk of persistent disease is greater when the lesion is large, or the patient is > 30 years of age or has...

  • E6/E7 mRNA testing for human papilloma virus-induced high-grade cervical intraepithelial disease (CIN2/CIN3): a promising perspective. Origoni, Massimo; Cristoforoni, Paolo; Carminati, Guia; Stefani, Chiara; Costa, Silvano; Sandri, Maria Teresa; Mariani, Luciano; Preti, Mario // Ecancermedicalscience;2015, Vol. 9 Issue 519-548, p1 

    . Since the introduction of biomolecular testing for the identification of high-risk human papillomavirus DNA (hrHPV-DNA) in cervical cancer preventive strategies, many interesting aspects have emerged in this field; firstly, HPV-DNA testing has been demonstrated to have better sensitivity than...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics